Jasmine Seror - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Role
VP Product Development
Signature
/s/ Jasmine Seror
Issuer symbol
CLGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 10:14:45 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seror Jasmine VP Product Development C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL /s/ Jasmine Seror 18 Mar 2026 0002120241

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CLGN Restricted Share Units 12,000 18 Mar 2026 Direct F2
holding CLGN Restricted Share Units 45,000 18 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 4,000 $4.02 Direct F1, F4
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 1,000 $4.02 Direct F1, F4
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 5,000 $6.39 Direct F1, F4
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 6,000 $6.39 Direct F1, F4
holding CLGN Options to Purchase Ordinary Shares 18 Mar 2026 Ordinary Shares 3,600 $6.39 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
F2 Of the restricted share units reported herein, 5,250 units are vested, and the remaining 6,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F3 The restricted shares shall vest over a period of 3 years: 33% shall vest on November 25, 2026, and the remaining 67% shall vest in eight equal quarterly installments thereafter.
F4 Fully vested and exercisable.